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Pharmacotherapy in paediatric epilepsy: from trial and error to rational drug and dose 
selection – a long way to go 
 
Introduction: Whereas ongoing efforts in epilepsy research focus on the underlying disease 
processes, the lack of a physiologically-based rationale for drug and dose selection contributes 
to inadequate treatment response in children. In fact, limited information on the 
interindividual variation in pharmacokinetics and pharmacodynamics of anti-epileptic drugs 
(AEDs) in children drive prescription practice, which relies primarily on dose regimens 
according to a mg/kg basis. Such practice has evolved despite advancements in paediatric 
pharmacology showing that growth and maturation processes do not correlate linearly with 
changes in body size. Areas covered: In this review we aim to provide 1) a comprehensive 
overview of the sources of variability in the response to AEDs, 2) insight into novel 
methodologies to characterise such variation and 3) recommendations for treatment 
personalisation. Expert Opinion: The use of pharmacokinetic-pharmacodynamic principles 
in clinical practice is hindered by the lack of biomarkers and by practical constraints in the 
evaluation of polytherapy. The identification of biomarkers and their validation as tools for  
drug development and therapeutics will require some time. Meanwhile, one should not miss 
the opportunity to integrate the available pharmacokinetic data with modelling and simulation 
concepts to prevent further delays in the development of personalised treatments for 
paediatric patients. 
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Article highlights 
 
* Despite the development of therapeutic guidelines for the treatment of epileptic seizures, 
AED selection and dose rationale for children remains empirical.  
 
* The use of dosing regimens in mg/kg does not correct for age-related changes in 
pharmacokinetics and pharmacodynamics in children, especially if one considers the use of 
polytherapy with two or more AEDs. 
 
* Inter- and intraindividual differences in pharmacokinetics and pharmacodynamics of AEDs 
need to be taken into account for the personalisation of treatment in paediatric epilepsy. 
  
* Whilst the identification of predictive biomarkers remains a challenging endeavour, 
quantitative clinical pharmacology methods can provide guidance for both anti-epileptic drug 
and dose selection. These methods allow for evidence synthesis, integration, and extrapolation 
of findings across different age groups, enabling better clinical decision-making and improved 
therapeutic response in children. 
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1. Introduction 
Epilepsy is a debilitating syndrome with an estimated 68 million people worldwide affected 
by it, which places the disease in the 7th position in terms of impact on disability and 
premature mortality among mental health, neurological, and substance-use disorders[1,2]. In 
addition, it takes the 19th rank out of 53 items accounting for the total costs for medical care 
generated in the area of neurology [3]. Whereas global figures may differ, recent prevalence 
data in the USA show that nearly 25% were children aged below 15 years of age [4]. 
Effective treatment and management of epileptic seizures has an important and direct impact 
on the quality of life of patients, especially those in the paediatric group. Despite the 
implementation and advancement of therapeutic guidelines, achieving such results remains a 
challenging objective. This situation prevails in the face of increasing understanding of the 
progression of the disease after onset in different age groups and introduction of regulatory 
requirements for the evaluation of efficacy and safety of AEDs in children [5,6]. 
 
1.1 Current drug and dose selection rationale in paediatric epilepsy	
Various guidelines exist on the diagnostic, management and treatment of epilepsies. However, 
only a few of them have focused on the use of antiepileptic drugs (AEDs) in children [7-9]. In 
fact, the British National Institute for Health and Care Excellence (NICE) guideline on 
epilepsy in children is the only document based on extensive review of the evidence for 
differences in efficacy and safety of each AED between types of epilepsy [9]. Even though 
recommendations are supported by evidence arising from randomised controlled trials, 
shortcomings are still evident. Many studies have been performed to show differences in 
efficacy and safety between seizure types, but no effective predictors have yet been found for 
differences in efficacy and safety within the same seizure type. This is likely the consequence 
of symptom-based criteria, which remain the foundation for diagnosis and AED treatment 
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selection. In addition, most paediatric trials rely on an “add-on approach”, with patients who 
may have more severe or refractory forms of epilepsy, which leads to inadequate evidence 
regarding the efficacy of monotherapy in treatment naive patients. This shortcoming is often 
compounded by the definition of response (clinical endpoint) in most clinical trials, which is 
based on a binary measure: responder (i.e., patients who show at least 50% of reduction in 
seizures compared to baseline) vs. non-responder. Dichotomisation of the response into two 
categories can be detrimental for the characterisation of dose-exposure-response relationships, 
especially if one considers that pharmacokinetic data are not collected systematically in 
efficacy trials. 
 
Whereas limited understanding of the exposure-response relationships might be mitigated by 
the clinical requirement for up and down-titration or tapering of the dose. In addition to 
reducing side effects and withdrawal symptoms, tapering procedures offer an opportunity to 
factor in the effect of interindividual pharmacokinetic and pharmacodynamic variability. Yet, 
this information is not fully integrated to support treatment personalisation. Currently, most 
formularies still rely on anecdotal (empirical) evidence of efficacy and safety in children. 
Dose recommendations in formularies, such as the Netherlands Kinderformularium or the 
British National Formulary for Children overlook the role of covariate factors and other 
sources of variability in pharmacokinetics and pharmacodynamics [10,11]. Clearly, there is a 
substantial amount of pharmacokinetic data regarding the use of AED in children, but even 
when taking into account correlations with weight and age, unexplained variability appears to 
remain high [12-14]. Similar challenges are faced when considering the adjustment of 
maintenance doses of AEDs. In spite of the use of therapeutic drug monitoring (TDM), which 
is widely accepted in paediatric epilepsy compared to adults, AED levels are checked against 
a therapeutic window, which was originally determined in adults. Moreover, these therapeutic 
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ranges ignore known to covariate effects, which may cause variability in exposure and 
potentially in the exposure-response relationship. 
One should also note the impact of variability in the status of the disease at the time of 
diagnosis and its progression, which are a hurdle for improved therapeutics and may possibly 
be associated with the  unnecessary exposure of paediatric patients to AEDs for years after the 
seizures have remitted [15]. Thus, the combination of unexplained variability in 
pharmacokinetics, pharmacodynamic and disease leaves clinicians without a clear dosing 
algorithm, other than the option to taper and adjust doses based on the clinical symptoms. 
The challenges a clinician faces to select the drug and dose regimen are illustrated in 
numerous publications on the efficacy and safety of AEDs in children [16-18]. In the next 
paragraphs we will highlight how dosing algorithms can be used as a valuable therapeutic tool 
before switching treatment or progressing to polytherapy.  
 
1.2 Personalised treatment of epileptic seizures: advancing clinical practice 
The ultimate goal of a (personalised) therapeutic intervention is to ensure a positive, if not 
optimal, balance between the expected benefits and risks of the treatment , taking into account 
the costs and the inherent uncertainties about favourable and unfavourable effects [19, 20]. 
This concept is particularly relevant when dealing with chronic diseases such as epilepsy, but 
little effort has been made to evaluate the impact of a one-size fits all approach on the overall 
effectiveness of antiepileptic drugs. In fact, one needs to recognise that heterogeneity in the 
disease makes it a case for exploring treatment options beyond current guidelines. For 
instance, some patients may achieve complete seizure remission with higher doses before 
adding on a second drug, but evaluation of higher doses requires more than empirical titration. 
It should be guided by dosing algorithms, which take into account the role covariate factors 
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associated with inter- and intraindividual variability in pharmacokinetics and 
pharmacodynamics.  
Unfortunately, formal assessment of the advantages of dosing algorithms for personalised 
treatment with AEDs is fraught with difficulties as it imposes the evaluation of changes in the 
benefit-risk balance (BRB). The determination of the BRB of a treatment requires precise, 
detailed information on the relationships between the dose, exposure and its favourable and 
unfavourable effects on the symptoms and signs of the disease. Given that the BRB of AEDs 
is not characterised in a quantitative manner during drug development, evidence arising from 
clinical practice may be too limited to allow accurate decision-making. Consequently, 
establishing criteria for the choice of the drug and the dose for the treatment of epileptic 
seizures in children cannot be performed adequately without quantifying the contribution of 
different sources of variability to heterogeneity in PK, PD, and disease, as discussed in 
previous paragraphs. Opportunities exist however to explore each of these factors (one by one 
and in combination) and subsequently evaluate the implications of different treatment options 
on the overall BRB. This can be achieved by means of model-based meta-analytical 
approaches including extrapolation and simulation scenarios in which patient characteristics, 
drug properties and disease features are integrated [19,21,22].   
 
The aims of this review are therefore to 1) discuss the impact of known sources of variability 
in PK, PD, and disease and 2) explore how quantitative clinical pharmacology concepts can 
be used to support the development of dosing algorithms to ensure that treatment choice and 
dosing rationale for paediatric patients are as effective as possible. We show that some 
improvement may be achieved in spite of the limitations of  current diagnosis criteria, lack of 
biomarkers and poor understanding of the mechanisms of action of AEDs. To this end, a 
structured literature search was performed in conjunction with supporting material from 
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clinical guidelines and regulatory documentation on the assessment of efficacy and safety of 
drugs in the paediatric population. The Pubmed search included MESH terms as well as 
individual and combined keywords. An overview of the initial search strategy is provided in 
Figure 1, where selection criteria are listed in a hierarchical manner to capture publications 
describing paediatric epilepsy, personalisation of treatment, pharmacokinetics, 
pharmacodynamics, pharmacogenetics, and biomarkers. Reviews as well as perspective 
papers were included in the analysis if relevant paediatric details were provided. When 
necessary, a separate search algorithm was used to identify publications on specific issues 
such as methodologies for data extrapolation and assessment of benefit-risk balance in 
children. If no relevant literature was retrieved, additional terms were included or excluded. 
The initial search resulted in a total of 145 articles, of which 56 were selected after screening 
the abstracts for relevance. These were complemented by an additional 70 publications, which 
were obtained from secondary queries and interactions with experts in paediatric clinical 
pharmacology.  
 
2. Intrinsic sources of variability and heterogeneity in response to AEDs 
Numerous hurdles have contributed to the emphasis in current practice regarding the use of 
seizure reduction (i.e., clinical response) for switching treatment and monitoring of systemic 
drug levels as the basis for modifying or individualising the dose and dosing regimen. Sadly, 
the notion that plasma levels, even at steady state, may not reflect differences in target 
exposure or pharmacodynamics is unfamiliar to most prescribing physician. This limitation is 
also critical for the development of new AEDs, as the evaluation of dose-response in clinical 
trials relies primarily on the assumption of target plasma levels and a predefined therapeutic 
range. In the next sections, we will discuss the implications of variability in pharmacokinetics, 
pharmacodynamics and in relevant physiological factors for the personalisation of treatment. 
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2.1 Pharmacokinetics 
The pharmacokinetics of a drug is determined by up to four physiological processes, namely 
absorption, distribution, metabolism and excretion (ADME). Metabolism and excretion are 
usually summarised by systemic clearance (plasma volume being cleared of the drug per time 
unit; CL). Summary measures of drug disposition is often limited to the so-called secondary 
pharmacokinetics parameters such as peak concentration (Cmax), trough concentration 
(Cmin), and mean steady state (Css/Cavg) concentrations, as well as the area under the 
concentration vs. time curve (AUC). It is important to note that secondary parameters are 
derived from primary PK parameters. For instance, following extravascular administration, 
peak concentrations depend on absorption rate, and volume of distribution, whilst Css and 
AUC are directly related to clearance. From a therapeutic perspective, response to AEDs is 
most likely explained by the average exposure or trough concentrations, with acute and some 
chronic side effects primarily being determined by peak concentrations. Hence, variability in 
the processes that determine drug disposition may affect treatment response.  In this respect, 
one needs to consider that some of these ADME processes are incomplete or immature at 
birth and young age, especially in pre-term infants [23,24]  (Table 1). Despite the impact of 
these factors on drug exposure, in most cases they are not included into the dose rationale for 
children. Details on the differences in the pharmacokinetics of specific AEDs in children can 
be found elsewhere [23, 25]. In the next paragraphs we describe the main factors determining 
the differences in ADME between adults and children, and overall variability in the PK of 
AEDs.  
 
2.1.1 Drug distribution: differences between plasma and target site concentrations 
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Plasma protein binding can be an important factor determining differences in 
pharmacokinetics, both with respect to drug distribution and clearance. In theory, only 
unbound drug concentrations distribute to the brain. Some authors have focused therefore on 
the free concentrations or free fraction of AEDs (for example carbamazepine [26], phenytoin 
[27], valproate [28]). In these publications, the free plasma concentration of the drug was 
found to better reflect the concentrations of the extracellular space and the brain’s interstitial 
fluid. However, brain distribution can be complex and variable depending on factors related to 
active transport mechanisms, disease-related changes in tissue permeability and other co-
morbidities. For instance, Clinkers et al. studied the influence of epileptic seizures on the 
concentration of oxcarbazepine in the hippocampus and in plasma in a rat model. [29]. 
Concentrations reached higher values in the interstitial space within the pilocarpine-induced 
acute seizures region and were even higher when oxcarbazepine was given in combination 
with a P-glycoprotein (Pgp) inbibitor. Most importantly, these differences were observed 
without significant changes in drug levels in plasma. These results illustrate the complex role 
of the functioning of the blood brain barrier (BBB) as a determinant of the target exposure. 
Indeed, up-regulation of the efflux transporter Pgp has been indicated as one of the possible 
explanations for the development of apparent tolerance [30]. 
 
Whereas active transport processes may determine tissue distribution, high variability in drug 
exposure can exist even between closely located areas in the brain. This was already described 
in 1978 in patients who had surgery after receiving carbamazepine in regular stable doses 
[31]. Rambeck et al. [32] analysed plasma, cerebrospinal fluid (CSF) and extracellular space 
(ECS) concentrations in to-be-excised live temporal brain tissue (in vivo with a microdialysis 
probe and ex vivo directly in the removed tissue) in patients refractory to treatment. As 
expected, brain extra-cellular concentrations were lower compared to plasma and CSF, which 
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demonstrates that the assumption of equal concentrations in CSF and ECS in one well 
distributed homogenous compartment is unjustified [33]. A general lack of information 
regarding differences in drug distribution in children, and particularly in infants and toddlers, 
(i.e., in the developing brain), as compared to adults renders the interpretation of treatment 
failure quite challenging, as lack of efficacy may not be a matter of refractoriness to therapy, 
but rather a pharmacokinetic problem. 
 
2.1.2 Clearance: influence of genotype, size, and maturation 
Inter-individual, and intra-individual variability in drug elimination processes mostly results 
from differences in the availability of the drug at the clearing organ, changes in the clearing 
capacity due to varying intrinsic clearance, and the size of the organ. 
Although it is known that organ perfusion varies with age [34], specific quantitative 
information regarding hepatic and renal changes are still sparse in some groups of the 
paedriatric population. Consequently, it is unclear to what degree variability in organ 
perfusion determines the changes in clearance between adults and children. Similarly, very 
limited information is available regarding AED protein binding in young children and its 
implications for differences in systemic clearance between adults and children [35,36]. 
Intrinsic clearance can also be influenced by polymorphisms in genes coding for metabolising 
enzymes which may lead to significant differences in hepatic clearance of many AEDs [37], 
with increase or reduction in metabolic capacity resulting in  different phenotypes [38]. 
Similarly, renal clearance can be affected by differences in the expression level of renal 
transporters [39,40]. Whilst the impact of such genetic differences can be accounted for when 
defining the dose and dosing regimen, genotyping or phenotyping are not used in standard 
practice when initiating or changing therapy, and is most probably not encouraged in children. 
Apart from the differences in the genetic make-up of the clearing organ, age-dependent 
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changes also affect the amount of drug that can be cleared. As a child grows organs develop 
both in terms of size and metabolic capacity (i.e., enzyme activity). It has been postulated that 
the influence of increasing size on clearance can, at least in part, be accounted for by 
adjusting for body weight. However, the relation between size (e.g. body weight) and 
elimination rate has been demonstrated to be non-linear. This implies that dosing in mg/kg 
does not accurately correct for the underlying differences [41]. In fact, unless explicit 
differences have been identified in the underlying pharmacokinetic-pharmacodynamic 
relationship, dose adjustment in children should aim at achieving comparable exposure or 
similar PK p rofile across the target population, irrespective of body weight or age.  One 
needs to be aware that whereas the use of weight-banded dosing regimens may be necessary 
to compensate for such nonlinearity, drug-drug interactions may have a higher impact on 
clearance than the effect of body size (Figure 2) [42–45]. 
 
2.2 Pathophysiology and pharmacodynamics 
Every brain is unique in its structure, connectivity, plasticity, and neurotransmitter 
homeostasis. As a result, wide intra- and inter-individual variation is observed in the response 
to CNS active drugs. Differences in physiology, whether genetic, congenital or acquired, can 
both give rise to epileptic seizures and affect one’s ability to respond to treatment. In fact, 
over the course of the disease, these differences as well as the progression of the underlying 
(patho-)physiological processes can change the way the brain responds to seizures, and 
consequently to therapy. In other words, variability in physiology begets variability in disease 
progression and treatment response, which in turn beget changes in physiology. Disentangling 
this circular web of interactions is perhaps the most challenging of the issues plaguing the 
field of AED therapy. Whereas characterising such interactions on an individual patient level 
may be unrealistic in the foreseeable future, personalisation of treatment may be achieved by 
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identifying disease-specific factors that are age-related or common to subgroups in the 
population. The impact of such concepts has been illustrated in a recent investigation by 
Pellock and collaborators who showed that evidence of efficacy in partial-onset seizures 
(POS) in adults can be used to predict drug response in children [5]. Yet, in other childhood 
epilepsies that persist or evolve to adulthood, changes in pathophysiology are not yet 
understood well enough to allow individual prediction of outcome. 
Another challenging aspect in the characterisation of interindividual differences is the nature 
of the interaction between drug and receptor or target. From a pharmacological point of view, 
pharmacodynamics (PD) describes the interaction between a drug and its target or receptor 
and the transduction mechanisms leading to a change in function. PD processes are a major 
determinant of the efficacy/safety profile of AEDs, but little is known about their (molecular) 
mechanisms. This is partly due to the fact that most AEDs have been discovered on the basis 
of phenotypic screening at a time when brain imaging and other innovative functional 
protocols were not available. Moreover, drug development in epilepsy has traditionally aimed 
at evaluating efficacy in adults. Only recently, changes in regulatory requirements have 
defined the need to characterise the efficacy and safety of AEDs in children. Such a sequential 
approach may however be inappropriate to address childhood-specific epilepsies. 
 
2.2.1 Assessment of anti-epileptic drug response: symptoms versus functional measures 
of brain activity 
In spite of the advances in imaging technologies, the evaluation of brain physiology in vivo 
remains a challenging undertaking. Although EEG is regularly used to identify pathological 
signs and confirm diagnosis, patients are not routinely subjected to a long-term biochemical 
and/or electrophysiological evaluation throughout the course of the disease and its treatment. 
Medical history (i.e. occurrence of seizures) rather than measurement of physiological 
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endpoints is used to support clinical evaluation and decision making regarding the choice of 
drug and dosing regimens.  
Clearly, the lack of data regarding the correlation between AED exposure, pharmacological 
effects (i.e. biomarkers) and therapeutic response (i.e. seizure reduction or suppression) makes 
it difficult for a physician to predict which treatment, and which exposure level, will work 
best for an individual patient or group. Close monitoring of the variation in response between 
patients over the course of treatment time is required to understand the role of differences in 
brain physiology. Such a monitoring imposes the availability of biomarkers which are 
sufficiently sensitive to detect variations in response as well as to predict treatment failure or 
toxicity. To date, the only known valid antiepileptic drug biomarker is HLA-B*1502, which is 
a strong predictor of Stevens-Johnson syndrome in patients of specific Asian backgrounds 
taking carbamazepine [46]. No other parameters exist with sufficient predictive performance 
for efficacy. 	 
 
Another point to consider in paediatric epilepsy is the role of neuronal maturation in the 
progression of epilepsy. Maturation and neurological development are processes that take 
place during growth. Changes in the expression of voltage gate dependent ion channels as 
well as structural changes associated with growth can have an impact on the sensitivity of the 
brain to a drug and consequently on the magnitude of drug effects [47]. Similarly, the time of 
diagnosis and initiation of AED therapy are potential causes of variability in treatment 
response. For example, the clinical management of seizures in the new-born has remained 
unchanged in spite of evidence that “classic” medications (phenobarbital and phenytoin) are 
largely ineffective (with more than half of the population being non-responders for both 
drugs) and potentially neurotoxic [48]. Most symptomatic seizures in neonates are due to 
hypoxic-ischemic encephalopathy and do not persist beyond the first few days of life. Due to 
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this natural improvement, any prompt intervention would appear effective and even curative. 
Such an apparent efficacy, which is wrongly attributed to the drug could be relevant across 
many types of epilepsy and result in AEDs being used more often than necessary, especially 
in the case of the developing brain of a new-born infant. This is particularly worrying if one 
takes into account the effect of AEDs on cognitive development and growth [49–53]. 
 
2.2.2 Disease progression and maturation 
In paediatric epilepsy, it is clearly the natural progression of disease varies not only between 
patients, but also between and within epilepsy subtypes and syndromes [54,55]. For instance, 
benign epilepsy with centrotemporal spikes (BECST) typically occurs between the age of 3 – 
14 years of age and resolves by age 17 despite the incidence of cognitive and behavioural 
disorders [56].  By contrast, Lennox-Gastaut syndrome begins between the age of 1-6, with 
seizures that generally do not respond well to treatment [57] Schmidt et al. estimated that 
without intervention, 20-44% of untreated epilepsies remit within one to two years [58]. Of 
the remaining patients, around 60% will respond favourably to therapy and the rest will 
present an insidious or recurrent syndrome in which approximately half of this subpopulation 
will not respond to treatment. Unfortunately, the authors seem to pay little attention to the 
differences between types of epilepsy and their aetiology [59,60]. Even more controversial are 
the prognostic factors for response to treatment, as only around 11% of patients with lack of 
efficacy to the first AED will respond to the second treatment option [15]. Without relevant 
biomarkers it is impossible to predict disease progression and/or treatment response. 
Consequently, clinical decisions regarding treatment choice and dose selection are determined 
by the disease status at time of the diagnosis or intervention. 
 
2.2.3 Target receptor polymorphisms, density, and adaptation 
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Many AEDs are believed to share a common mechanism of action through the interaction at 
the receptor level, usually an ion channel on the surface of the target neurons [61]. In addition, 
it can be assumed that caeteris paribus the higher the target engagement the stronger the 
signal being transmitted or blocked. Consequently, the exposure-response curve of an AED in 
vivo will vary depending on the availability (density) of receptors [62]. Additional variability 
may arise from polymorphisms of target receptors (which can be caused by differences in the 
aetiology of epilepsy) as well as from variable binding kinetics at the target. Indeed, changes 
to binding kinetics can alter drug potency, which in turn affects the dosing requirements [63]. 
From a clinical perspective, it should be highlighted that epileptic patients often experience a 
decreased drug effect over the course of treatment, which cannot be explained by the 
aforementioned processes or mechanisms. This reduction may be a gradual process, but often 
occurs suddenly, possibly after discontinuation and reinstatement of drug therapy. One of the 
potential causes of pharmacoresistance is down/up regulation of the target receptors  [64–66]. 
In these circumstances, whereas increases in the dose may off-set the effects of down-
regulation, higher drug exposure may lead to side effects, preventing achievement of 
satisfactory response levels. Pharmacoresistance has been reported to affect about 23% of 
paediatric patients [67], whom respond better to surgical intervention than adults. [68]. 
 
3. Extrinsic sources of variability and heterogeneity in response to AEDs  
Apart from the biological factors implicated in previous sections, some extrinsic factors limit 
our understanding of the PKPD relationships of AEDs and consequently may affect treatment 
choice and dose selection for the paediatric population. Here we focus on the implications of 
food-drug and drug-drug interactions, as well as on the impact of variable treatment 
adherence. 
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3.1 Drug-food interaction and formulation variability 
Most used AEDs have been off-patent for some time and thus generic versions exist in all 
kinds of formulations. Although the pharmacologically active substance is the same, and 
bioequivalence studies should provide evidence for similar exposure to the drug, different 
formulations have been introduced, which are intended to modify drug release profile and as 
such can lead to faster or slower absorption  possibly resulting in different peak 
concentrations [69] and consequently in a different safety profile [70]. This issue can be 
compounded by small differences in the bioavailability (fraction of the dose that is absorbed 
and reaches the systemic circulation) of AEDs (Figure 4)[71]. For example, the bioavailability 
of carbamazepine is considered to be 80% on average, but ranges considerably [72]. In the 
case of gabapentin, bioavailability is inversely proportional to the taken dose, resulting in 
reduced increases in exposure with increasing doses [73]. Finally, absorption and first pass 
metabolism can be influenced by food intake and beverages, such as grapefruit juice [74]. 
These factors are difficult to control but can contribute to overall variability in the exposure to 
AEDs. Thus, to minimise the influence of absorption kinetics on the disposition of AEDs, 
many extended-release formulations have been developed for adult patients, which reduce 
peak/trough concentration ratios while maintaining similar overall exposure. By contrast, 
extended release tablet formulations are not always an option in children, as swallowing such 
tablets can be too difficult for younger patients. This limitation could be overcome by 
specially designed liquid extended-release formulations [75]. 
 
3.2. Drug combinations and drug-drug interactions  
Current clinical guidelines recommend drug combination or polytherapy only in those cases 
in which monotherapy is proven to be insufficiently effective. In the case of effective 
polytherapy, it is suggested to taper off the previous treatment to achieve monotherapy over a 
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longer time interval. Monotherapy is therefore assumed to be the best treatment choice, but 
this practice does not take into account the possibility of pharmacodynamic interactions, and 
in particular, synergy, for which some evidence exists [76–78]. Combining drugs with a 
different mechanism of action may offer the best chance of achieving synergistic interactions, 
although there is scarce evidence for this concept from clinical trials [79]. These claims occur 
despite the lack of consensus on whether patients might benefit of an alternative drug or 
multiple AEDs [80]. On the other hand, pharmacokinetic drug-drug interactions (DDI) have 
been identified for many AEDs. Consequently, it may be challenging to disentangle changes 
in drug effects due to a pharmacodynamic interaction from the effects associated with changes 
in the exposure due to the primary AED. Given safety and ethical constraints, the 
characterisation of possible pharmacodynamic interactions remains difficult in a clinical 
setting. 
 
3.2 Adherence to treatment 
Treatment with AEDs often leads to cognitive, behavioural and physical adverse effects [81]. 
When such effects are experienced as burdensome, it is likely that a patient will not comply 
with the prescribed regimen and take short or longer drug holidays, leading to poor 
persistence and eventually discontinuation of treatment [82]. Whereas some of these adverse 
effects can be prevented or reversed by adjusting the dose correctly for the individual patient 
or group, limited information is available on the impact that drug holidays have both on the 
efficacy and safety profile of AEDs. This issue is further compounded in paediatric epilepsy, 
as adherence does not involve on the patients themselves, but parents or caregivers who can  
also interfere with drug intake. In fact, random missingness of the dose during a single day of 
treatment can already decrease exposure levels significantly. A recent study has found that 
approximately a quarter of the paediatric patients are nonpersistent in taking their prescribed 
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AED therapy, but the impact of variable adherence on treatment outcome was not evaluated 
[83].  
Given that poor adherence is often not disclosed by patients, physicians may attribute a 
potential loss of efficacy to disease or pharmacodynamic factors, rather than to variation in 
drug exposure due to variable patterns of drug intake. In this case, patients may be 
recommended a dose increase or an alternative treatment, which may result in increased 
incidence of adverse effects [82]. Open, honest communication between physician, patients 
and parents when necessary is therefore critical to minimise the risk of inaccurate treatment 
decisions [84]. 
 
4. Conclusion 
Children are not small adults and it is known that syndromes in paediatric epilepsy undergo 
variable progression and changes in the natural course of the disease due to 
neurodevelopment. Changes in pharmacokinetic, pharmacodynamic and physiological 
processes associated with maturation and developmental growth determine the differences in 
response to AED treatment in this population. Many of these changes occur concurrently, 
preventing accurate prediction of the response (and prognosis) at an individual patient level. 
An integrated approach, supported by potential biomarkers and dosing algorithms is needed to 
ensure appropriate selection of drug(s) and dose for a specific patient or group of patients. 
Regardless the large amount of data collected on existing and new AEDs, knowledge is not 
sufficiently integrated to support the implementation of treatment personalisation. This lack of 
integration prevails, despite efforts by health technology assessment organisations to establish 
the effectiveness of available medicines. Guidelines such as NICE rely on published evidence, 
which may lag considerably behind the introduction of a new medicinal product into clinical 
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practice. Moreover, such guidelines are not fit-for-purpose, i.e., do not specifically focus on 
subgroups in such a way that fully supports the use of personalised treatments in children.  
To allow paediatricians to better decide on which AED(s) to prescribe and at which dose, a 
novel approach is required that takes into account the aforementioned complexities of 
epilepsy [85]. A promising, readily available methodology for the selection of a drug and 
dosing regimen is PKPD and disease modelling [86]. However, to be an effective resource for 
treatment personalisation, biomarkers must be identified that are sensitive to the disease state 
and progression, so that efficacy and toxicity of drugs can be better characterised in clinical 
practice. Undoubtedly, the availability of biomarkers would also represent an advancement to 
diagnosis, minimising the need for a trial-and-error approach to pharmacotherapy [87–90]. In 
our expert opinion, we explore how the application of model-based algorithms may achieve 
these goals. 
 
5. Expert Opinion 
 
5.1. Definition of treatment response and assessment of efficacy and safety 
Seizure frequency or similar continuous measures be considered as primary endpoints for the 
assessment of efficacy. The use of number of responders, i.e., patients achieving a decrease in 
seizure count of at least 50% at the end of the study relative to baseline and the percentage of 
the population that achieves such “seizure control” compared to placebo or a control treatment 
are not sufficiently informative.  Such a dichotomisation of the response results in a loss of 
information, as it does not allow the characterisation of the drug effect at the individual 
patient level. As a result, personalisation of treatment, including dosing recommendations 
cannot be derived unless a broad dose range is tested and stratified for. Such a requirement is 
unrealistic as more patients would be required for adequate evaluation of response in a 
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clinical trial. This limitation is further compounded by bias in the comparison between 
experimental and control treatments when applying the aforementioned response criteria [91]. 
In addition to the use an endpoint which offers more granularity to the evaluation of efficacy, 
experimental protocols need to be revisited. Typically, the efficacy of new AEDs is tested in a 
so-called “add on” trial design, in which patients who are refractory to treatment receive the 
new drug. This complicates the interpretation of the results for a variety of reasons. First, it 
introduces selection bias in drug potency and on the required dose recommendations. In 
patients who are refractory to treatment, response is expected to be less than in non-refractory 
patients. Moreover, the observed response is the result of a combination of the direct effect of 
the drug and/or an interaction with the background treatment. As a result, interactions must be 
taken into account to establish the magnitude of the effect of the new drug in the absence of 
other AEDs. These limitations apply a fortiori in children. Ethical considerations make it 
virtually impossible to evaluate efficacy and safety in children according to typical Phase IIb 
dose ranging studies. 
 
5.2 Understanding and predicting variability 
L.B. Sheiner envisioned a learning-confirming paradigm [92] in which available prior 
information is first used to learn by prediction or extrapolation using modelling and 
simulation techniques (evidence synthesis), where possible taking into account multiple 
sources of information (integration). An experiment can then be optimised to address the gaps 
in knowledge (evidence generation), the outcome of which is then used to confirm the 
predictions and build new theories and models (Figure 4). More specifically with regard to the 
use of AEDs in paediatric epilepsy, accurate predictions of treatment response may be 
achieved as a result of systematic integration of data on pharmacokinetics, pharmacodynamics 
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and disease [93]. Such an approach may have direct implications for the implementation of 
personalised treatments, including dosing algorithms for paediatric patients. 
 
The use of PKPD and disease models relies on current understanding of the disease and 
pharmacology. Usually, one endeavours to describe the biological system of interest with 
sufficient detail to ensure accurate predictions for a range of possible interventions. This 
process relies on a set of assumptions is often referred to as parameterisation and is aimed at 
identifying descriptors of the physiological or pharmacological effects in a simple, but yet 
robust manner. For instance, using a PK model instead of collecting and summarising drug 
concentrations only, it is possible to predict the time course of the drug concentrations 
following drug administration of different doses and dosing regimens, as well as better 
account for the impact of covariates such as body weight or age.  Similarly, PKPD and 
disease models provide the basis for the assessment of the interaction between drug and 
biological system, taking into account the progression or changes associated with the disease 
itself. Such parameterisation also allows one to quantify the impact of influential factors on 
parameter values and describe them as covariates. The incorporation of covariates into a 
PKPD or disease model has an important advantage in that it enhances the prediction of 
response for specific groups of patients [94–96]. In conjunction with clinical trial simulations, 
model-based techniques offer an excellent opportunity for the evaluation of novel therapies 
[97] as well as personalisation of the dosing regimen for children [98]. 
 
5.2.1 Personalised treatment 
Clinical  guidelines for epilepsy [99] still rely on diagnostic criteria which are primarily 
determined by symptoms, Consequently, AED treatment selection is based on the underlying 
epileptic syndrome, as defined by the type of epileptic seizures (e.g. partial, primary or 
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secondary generalised, absence, etc.) and age (adults, children, etc.), with aetiology playing 
only a minor role. For each syndrome group, multiple lines of treatment are considered. Given 
the heterogeneity in the aetiology of the disease within each group, it is likely that the 
different treatment options simply reflect the uncertainty about the interindividual differences 
in response.  
A more mechanistic approach is required for the classification of seizures, as it would 
facilitate the distinction between AEDs which can modify the disease from those which act on 
symptoms [100]. The use of disease modelling can also contribute to another pressing issue, 
i.e., the nature and magnitude of the effect of drug-drug interactions. It has been proposed that 
combining AEDs with different mechanisms of action might have a synergistic effect 
compared to combining those with a similar mechanisms of action, but no research has 
conclusively supported this idea [101]. By contrast, others have suggested a more practical 
approach of exploring doses and combinations in difficult refractory cases [102]. A more 
aggressive pre-emptive intervention may very well be the answer to treatment resistant 
epilepsy, but no systematic studies are available to support this hypothesis. Despite concerns 
about the use polytherapy, the concept is appealing especially in children if evidence can be 
gathered of the implications of early interventions with multiple AEDs.  Advancements will 
only become tangible after sensitive biomarkers have been identified. In conjunction with 
disease modelling, biomarkers may also allow one to discriminate the contribution of one of 
more compounds to the overall response and determine whether AEDs affect disease 
progression.  
In the absence of biomarkers, long term longitudinal (observational) studies represent an 
important step to further characterise the pros and cons of a given intervention. It is 
regrettable that no attempts have been made to apply disease modelling concepts to 
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(pharmaco)epidemiological studies. Despite the retrospective nature of such an approach, 
important insight may be gained about predictors and determinants of response in children. 
 
5.2.2 Personalised dose and dosing regimen 
As previously stated, 10-20% of refractory patients can benefit from dose adjustments [15], 
but little discussion exists in the literature regarding appropriate dosing in non-refractory 
patients. In fact, it is likely that in numerous cases the lack of response to AEDs may occur 
due to inadequate dosing, whereas other patients may experience adverse events due to 
overexposure. Efforts from therapeutic drug monitoring have not addressed this issue and 
caused PK considerations to be misinterpreted during clinical decision about the dose and 
dosing regimen of AED. Most importantly, limited attention is given to the role of covariates 
that are known affect PK and potentially alter the efficacy and safety profile of an AED.  
 
Since therapeutic concentration ranges for each AED are available in literature, such data can 
be used with PK models, including the contribution of covariates to identify suitable titration 
and maintenance dosing algorithms. Unfortunately, these therapeutic concentration ranges 
were generally determined in the adult population, making their relevance for the different 
epilepsy subtypes in the paediatric population questionable. The development of dosing 
algorithms is particularly important for the paediatric population, irrespective of the lack of 
further data on exposure-response and exposure-toxicity relationships. A major benefit from 
this approach is the opportunity to provide recommendations for dosing adjustment taking 
into account complex drug-drug interactions in a strictly quantitative manner; this issue is 
poorly addressed by current therapeutic guidelines. In this context, simulation scenarios can 
also be explored to predict the response to drug combinations also in refractory patients.  
Whilst one needs to acknowledge the role of disease progression over time in paediatric 
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epilepsy, efforts to ensure comparable exposure to drugs, irrespective of their age or body 
weight, represent a more robust approach than trial and error in a vulnerable patient 
population. 
We also note that despite the considerable number of publications aimed at PK modelling of 
AED, most authors offer this as a somewhat technical description of ADME properties of the 
drugs. Most publications lack insight into core clinical pharmacology issues and do not 
expand their analysis and interpretation to meet clinical needs such as dose rationale and 
implications for prescription practice. In summary, the information available is not being 
integrated and most importantly, the lack of a “big picture” regarding core clinical 
pharmacology principles seems to perpetuate the gaps in data generation, i.e., missing 
information is not being generated. Figure 5 depicts the steps required to ensure personalised 
treatment, with a stronger rationale for drug and dose selection. Clinical dosing could be 
enhanced by algorithms, which are more efficient than typical titration procedures and 
therapeutic drug monitoring (TDM). Combined with dried blood spot or saliva analysis 
techniques, the burden of TDM on the paediatric patient could be minimised. [103,104] The 
benefits of a model-based approach are illustrated in a simulation study [online supplement 
1], using published data as an example of what dosing algorithms can represent to clinical 
practice in paediatric epilepsy [105]. Clearly, effective implementation of dosing algorithms 
imposes further integration of existing and new evidence on the efficacy and safety of AEDs. 
It also demands for extrapolation tools and evidence generation based on more informative 
experimental protocols. The potential impact to such efforts is highlight in the following 
paragraphs. 
 
5.3 Evidence synthesis 
5.3.1 Integration of historical and new evidence 
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One of the most powerful characteristics of model-based approaches is the possibility of 
integrating information from different sources and combining them with statistical concepts to 
make predictions about new scenarios, beyond the experimental evidence available from the 
data itself. Given the complexity of epilepsy’s many interacting factors, these techniques 
represent a valuable research tool in this field. Currently, its use remains, however, limited to 
pharmacokinetic data analysis. 
 
5.3.2 Extrapolations  
Translational medicine can be defined as extrapolating findings from basic science and 
quickly making them useful for practical applications that enhance human health [106]. 
Whilst its implementation is often limited to stand-alone experimental protocols, translational 
steps can be achieved by the use of model-based extrapolations [107,108], The use of 
extrapolations based on clinically and biologically plausible assumptions can make 
translational medicine a valid and powerful tool. The approach involves appropriate scrutiny 
by simulation exercises  enabling the integration of different types of data, such as pre-clinical 
in vitro (cell lines, tissue, organs), in vivo (mice, rats, dogs, etc.) and clinical data [109, 110]. 
Of interest is the role that extrapolations can have to characterise differences and similarities 
between paediatric and adult patients [111-113].  As recently defined by the European 
Medicines Agency (EMA), extrapolation may be generally defined as: “Extending 
information and conclusions available from studies in one or more subgroups of the patient 
population (source population), or in related conditions or with related medicinal products, to 
make inferences for another subgroup of the population (target population), or condition or 
product, thus reducing the need to generate additional information (types of studies, design 
modifications, number of patients required) to reach conclusions for the target population, or 
condition or medicinal product” [6].  
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It should be clear that the primary rationale for extrapolation is to avoid unnecessary studies 
in children. However, extrapolations are not generally acceptable as a default approach [Table 
2]. As discussed previously, an interesting finding in epilepsy is the extrapolation of efficacy 
results in adults to predict a similar adjunctive treatment response in 2- to 18-year-old 
children with partial onset seizure [5]. 
 
5.4 Evidence generation 
An important shortcoming of the primary measure of efficacy is the fact that seizure reduction 
from baseline does not reflect changes in epileptic activity in the brain in a strictly 
quantitative manner nor does it relate to the mechanism of the drug on such processes. In fact, 
a more careful evaluation of this criterion may not be comparable across all subpopulations 
[114]. Clearly, early, sensitive biomarkers and endpoints are essential to accurately 
characterise interactions of drug(s) and disease. One needs to establish how drug effects 
interact with the underlying disease and explore whether longitudinal changes in such 
endpoints can be used to predict long term response to treatment. So far, very few attempts 
have been made to identify predictors of response or treatment failure; such investigations 
have however relied on seizure reduction or establish the potential prognostic rather than 
predictive value of the variables of interest (Figure 3) [115]. Therefore we strongly support 
the views that clinical research protocols need to integrate clinical measures to markers of 
physiological and pharmacological effects of AEDs. In this context, imaging techniques need 
to be coupled to the evaluation of efficacy in clinical trials. Functional magnetic resonance 
imaging (fMRI) and positron emission tomography (PET) represent promising opportunities, 
but their evaluation as biomarkers in epilepsy has not yet been fully explored [116–118] and 
may be too burdensome to use in paediatric epilepsy.   
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A final point to consider in evidence generation is the informative value of data, which should 
include, rather than exclude relevant covariates and influential factors on exposure-response 
relationships. Numerous examples exist where early adoption of modelling and simulation has 
led to better trial design, in particular with regard to the dose selection and characterisation of 
influential factors on PK , PD and response [121,122]. Although successful studies have been 
conducted to derive paediatric dosing based on empirical designs, others failed and possibly 
could have been successful based on modelling and simulation [123–125]. In summary, 
clinical researchers and regulators need to acknowledge the limitations of traditional protocols 
to evaluate efficacy and safety of AEDs in children [126–128]. Effective implementation of 
personalised treatment for the paediatric population requires concerted efforts to ensure that 
experimental data are generated and integrated beyond traditional statistical hypothesis 
testing. Lessons can be learned from recent developments in oncology [129], where clinical 
trials, treatment and dose selection have undergone major advancements both conceptually 
and clinically over the last decade. 
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Table 1. Pharmacokinetic characteristics of commonly used antiepileptic drugs (adapted from 
[24]). 
 
Table 2. Acceptability of different extrapolation approaches for the prediction of disease 
progression, pharmacodynamics and pharmacokinetics between and within species. 
 
 
Figure 1. The diagram depicts the search strategy, including MESH terms and keywords used 
to select the publications included in this review. 
 
Figure 2. An example of the complex interaction between multiple covariates on the clearance 
of lamotrigine. In this diagram lamotrigin dose-corrected concentrations (DCC) are stratified 
by groups: Group 1, samples with VPA co-medication; Group 2, samples with LTG metabolic 
inducers (inducers) (CBZ, PHT, or PB); Group 3, samples with antiepileptic drugs other than 
VPA and inducers (CBZ, PHT, or PB); Group 4, samples with VPA and inducers (CBZ, PHT, 
or PB); and Group 5, samples with LTG monotherapy.  The bottom and top of each box show 
the 25th and 75th percentiles, respectively. The horizontal line in each box indicates the 
median. The groups are indicated by the dotted lines. The horizontal lines in the upper part of 
the figure indicate significant differences between groups (*p < 0.001, **p = 0.01).  Among 
patients with VPA (Group 1) and inducers (Group 2), the DCC of LTG is lower in cases 
under 6 years old (adapted from [42]) 
  
Figure 3. In this example, plots show the relative hazard ratio for age and total number of 
seizures before randomisation for the time to treatment failure. Hazard ratio estimates with 
95% CIs are shown for overall time to treatment failure, for age (A) and total number of 
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seizures (B), and for time to treatment failure because of inadequate seizure control and 
because of unacceptable adverse events, for age (C) and total number of seizures (D). Ideally, 
biomarkers should be identified that can be used as predictors of response or failure without 
the need to measure the reduction in seizure frequency. 
 
Figure 4. (a) Dose and concentration relationship of (a) gabapentin (n = 189), ref. range 
(70–120 mmol/L) and (b) pregabalin (n = 167), ref. range (10–30 mmol/L) (with permission 
from [71]). 
 
Figure 5. Information on disease processes, pharmacodynamics and pharmacokinetics must be 
integrated to ensure accurate personalisation of AED treatment and rational dose selection in 
children. Whereas interindividual differences in disease and pharmacodynamics of AEDs play 
an important role in treatment selection, understanding of the effect of developmental growth 
and maturation processes is essential for the selection of the paediatric dosing regimen. 
Table 1. Pharmacokinetic characteristics of commonly used antiepileptic drugs (adapted from [24]). 
Drug 
 
Time to steady 
state (d) 
Half-life 
(h) 
Tentative therapeutic rangea Major route of elimination 
(µmol/L) (µg/mL) 
Felbamate 3-5 14-22 125-250 30-60 Oxidation and renal excretion 
Gabapentin 2 5-7 70-120 12-20 Renal excretion 
Lamotrigine 3-15 8-33 10-60 2.5-15 Glucuronide conjugation 
Levetiracetam 2 7-8 35-120 8-26 Renal excretion and hydrolysis 
Oxcarbazepine 2-3 8-15 50-140b 12-35 Keto-reduction, then glucuronide conjugation 
of MHD 
Pregabalin 2 6-7 NE 2.8-8.2 Renal excretion 
Tiagabine 2 7-9 50-250c 20-100d Oxidation 
Topiramate 4-6 20-30 15-60 5-20 Renal excretion, oxidation 
Vigabatrin 1-2 5-8 NA NA Renal excretion 
Zonisamide 5-12 50-70 45-180 10-38 Glucuronide conjugation, acetytation, 
oxidation and renal excretion 
a The lower limit of the therapeutic range is of limited value, because many patients do well at serum concentrations below this limit. 
b Monohydroxy derivative. 
c nmol/L. 
d ng/mL. 
MHD = monohydroxy metabolite;  NA = not applicable;  NE = not established 
 
Table 2. Acceptability of different extrapolation approaches for the prediction of disease 
progression, pharmacodynamics and pharmacokinetics between and within species. 
 
Extrapolation of From To Acceptability References 
Disease mechanisms and PD animals humans Unclear [59,60,109,113,115]
Disease progression and PD 
with similar aetiology 
adults children Possibly [5,116] 
Disease progression and PD 
with different aetiologies 
adults children Not acceptable [117] 
Pharmacokinetics 
(allometrically) 
animals humans Possibly  [118] 
Pharmacokinetics 
(allometrically) 
adults children 
>3yo 
Probably [13,119,120] 
>3yo: older than 3 years 
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Figure 2. An example of the complex interaction between multiple covariates on the clearance of 
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PB); Group 3, samples with antiepileptic drugs other than VPA and inducers (CBZ, PHT, or PB); Group 4, 
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Figure 3: In this example, plots show the relative hazard ratio for age and total number of seizures before 
randomisation for the time to treatment failure. Hazard ratio estimates with 95% CIs are shown for overall 
time to treatment failure, for age (A) and total number of seizures (B), and for time to treatment failure 
because of inadequate seizure control and because of unacceptable adverse events, for age (C) and total 
number of seizures (D). Ideally, biomarkers should be identified that can be used as predictors of response 
or failure without the need to measure the reduction in seizure frequency.  
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Case study: PKPD of topiramate in children – Does dose adjustment help? 
 
1. Introduction 
Many patients do not respond to first line anti-epileptic drug (AED) treatment and then have to go through cycles 
of trial and error to find the treatment that works for them. In case the first line treatment fails, a TDM sample 
can be taken and compared to the therapeutic window of the drug. If the sample AED concentration is below the 
therapeutic window, the dose is increased, but in case it’s within the therapeutic window, the drug is often 
tapered off and substituted by another one.  It is unreasonable to think that efficacy is homogenous across the 
range of the therapeutic window. Instead, increases in dose can result in improvement in efficacy even when the 
TDM sample was within the therapeutic window[1].  In fact, for topiramate (TPM), the efficacy has been related 
to the trough concentrations in a literature PKPD model[2].  In this exercise, we aim to use simulations of 
topiramate PKPD to investigate how choices in dosing can alter the apparent efficacy of the AED, and determine 
how model-based treatment choices can improve dosing rationale and subsequent clinical response. 
 
2. Methods 
2.1. Population PK and PD 
The TPM pharmacokinetic/pharmacodynamic (PK/PD) model developed by Girgis et al. [2] is one of the few 
PK/PD models available for AEDs in literature. They describe its PK using a typical two compartment model 
with first order absorption and elimination (equations 1.1-1.5 & 2.1-2.5, figure 1, table 1), which can be used to 
predict the concentration over time for each day for each individual, after which the minimum concentration for 
each day for each individual can be determined (Cmin). This Cmin is then coupled to response (odds of the 
individual not having had a seizure since inclusion) using a logarithmic function (equation 4) that depends on the 
baseline number of seizures per 3 months. 
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Figure 1. 2 compartmental structure of the Girgis TPM PK model 
 
 
ṥṷ ൌ ߠῺ ∗ ሺ1 ൅ ṡṧṳ ∗ ߠῼሻ ∗ ቀௐ்ᾮᾫ.ᾫቁ
ఏయ ∗ ⱡఏర∗ሺᾡ௚௘ିᾨῺ.ᾬሻ ∗ ߠᾪூேெᾧ ∗ ߠᾮ௏௉ᾡ ∗ ߠᾩேῴெᾧ ∗ ⱡఎҲӃ,Ӳ   (1.1) 
ẑῺ ൌ ߠᾭ ∗ ቀௐ்ᾮᾫ.ᾫቁ
ఏవ ∗ ⱡఎӘభ,Ӳ          (1.2) 
ⱴ௔ ൌ ߠῺΏ ∗ ⱡఎӶӢ,Ӳ           (1.3) 
ⱴῺῼ ൌ ߠῺῺ           (1.4) 
ⱴῼῺ ൌ ߠῺῼ           (1.5) 
Ka: absorption rate constant, CL=clearance, V1: volume of central compartment, K12: rate constant of 
distribution from central to peripheral compartment, K21: rate constant of distribution from peripheral to central 
compartment, ADJ=TPM given as adjunctive therapy (1=yes,0=no), WT=weight in kg, Age=age in years, 
INMD=inducing medication given (such as carbamazepine, phenobarbital or phenytoin, 1=yes, 0=no), 
VPA=valproate/valproic acid given (1=yes,0=no), NEMD=no effect medication given (such as zonisamide, 
1=yes, 0=no). 
 
ߙ ൌ ௞మభ
ҲӃ
Әభ	
ఉ            (2.1) 
ߚ ൌ Ὼῼ ൬ⱴῺῼ ൅ ⱴῼῺ ൅
ᾣ௅
௏భ െ ┐ሺⱴῺῼ ൅ ⱴῼῺ ൅
ᾣ௅
௏భሻῼ െ 4ⱴῼῺ
ᾣ௅
௏భ       (2.2) 
ṡ ൌ ௞Ӣ௏భ
௞మభିఈ
ሺ௞Ӣିఈሻሺఉିఈሻ          (2.3) 
ṣ ൌ ௞Ӣ௏భ
௞మభିఉ
ሺ௞Ӣିఉሻሺఈିఉሻ          (2.4) 
ṥ௧ ൌ ∑ ṧ௜൫ṡⱡିఈሺ௧ି௧ҴӲሻ ൅ ṣⱡିఉሺ௧ି௧ҴӲሻ െ ሺṡ ൅ ṣሻⱡି௞Ӣሺ௧ି௧ҴӲሻ ௡௜ୀῺ      (2.5) 
i: ith dose, n=number of doses. t=time, tDi: time of dose i. 
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Table 1. Parameter values and variance (CV%) of the Girgis TPM PK model 
Parameter (unit) Value CV% 
CL: Clearance (L/h) 
θ1 1.21 27.28 
θ2 0.479 
θ3 0.453 
θ4 -0.00306 
θ5 1.94 
θ6 0.686 
θ7 0.635 
V1: Central volume of distribution (L) 
θ8 4.61 116.2 
θ9 1.14 
Ka (/h) 
θ10 0.105 22.34 
K12: Distribution rate constant 
to the peripheral compartment (/h) 
θ11 0.577 - 
K21: Distribution rate constant 
from the peripheral compartment (/h) 
θ12 0.0586 - 
 
 
ߣΏ ൌ ߠῺᾨ           (3.1) 
ߣ௧ ൌ ߠῺᾬ           (3.2) 
ߣᾣӺӲӼ ൌ ߠῺᾪ           (3.3) 
ߣᾥௌᾨିῺΏ ൌ ߠῺᾮ           (3.4) 
ߣᾥௌῺΏ ൌ ߠῺᾩ           (3.5) 
log	ሺߣ௜ሻ ൌ ߣΏ ൅ ߣ௧ ∗ ݐ ൅ ߣᾣӺӲӼ ∗ ṥ௠௜௡,௜ ൅ ߣᾥௌᾨିῺΏ ∗ ṣẋᾨିῺΏ,௜ ൅ ߣᾥௌῺΏ ∗ ṣẋῺΏ,௜    (3.5) 
λi: hazard of individual i, t: time (weeks), Cmin,i: minimum TPM concentration in individual i, BS3-10,i: baseline 
between 3-10 seizures per 3 months (1=yes,0=no), BS10,i: baseline more than 10 seizures per 3 months 
(1=yes,0=no). 
 
Table 2. Parameter values of the Girgis TPM PD model 
Parameter Value 
θ13  (ߣΏ) -3.130 
θ14  (ߣ௧) -0.051 
θ15  (ߣᾣӺӲӼ) -0.112 
θ16  (ߣᾥௌᾨିῺΏ) 1.048 
θ17  (ߣᾥௌῺΏ) 2.411 
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2.2. Exploratory pharmacokinetic simulations 
TPM concentrations were simulated for virtual paediatric patients receiving 2.5, 5 or 7.5 mg/kg bi-daily (5, 10, 
15 mg/kg/day respectively) of TPM doses for 31 consecutive days, each dose level simulated for 100 patients per 
dose level. Patients had ages ranging (uniformly sampled) between 4-14 years, and corresponding weights 
sampled from a normal distribution with mean 3*Age+7 and a coefficient of variance of 25%. 
 
2.3. Exploratory pharmacodynamic simulations 
Clinical response (number of patients not having any seizures during 1 month) was simulated for virtual 
paediatric patients with different baseline seizure levels (0-3, 3-10, or more than 10 per month) receiving 2.5, 5 
or 7.5 mg/kg bi-daily (5, 10, 15 mg/kg/day respectively) of TPM doses for 31 consecutive days, each dose level 
simulated for 100 patients per baseline seizure rate level. In total, 9 scenarios were simulated (3 dose levels * 3 
baseline seizure levels), with 100 patients per scenario. Patients had ages ranging (uniformly sampled) between 
4-14 years, and corresponding weights sampled from a normal distribution with mean 3*Age+7 and a coefficient 
of variance of 25%. 
 
2.4. Simulation scenarios 
Two scenarios were selected, scenario 1 simulating an approximation of current clinical practice, and scenario 2 
simulating model-based individualized medicine. One hypothetical population of 1000 typical 4-14 year old 
patients with corresponding weights (as above) and baseline seizures per 3 months as in Girgis et al. were 
simulated, which were kept identical for both scenarios. The impact of treatment regimens was simulated and at 
the end of every treatment period of 4 weeks the percentage of treatment success and failure was calculated for 
each scenario. For the sake of simplicity, up-titration was not simulated, i.e. patients were directly initiated on 
their target dose. 
 
2.4.1. Scenario 1 
After treatment with the initial target dose of 5 mg/kg/day for 28 days, a decision was made based on whether 
the patient had seizures in those 28 days or not. Patients who had a seizure had their dose increased to 10 
mg/kg/day. Those receiving 10 mg/kg/day still having had a seizure after another 28 days, had their dose 
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increased one last time to 15 mg/kg/day. If after another 28 days seizures still had occurred, the treatment was 
believed to have failed and the patient was switched to another AED. 
 
Figure 2. Representation of scenario 1 
 
2.4.2. Scenario 2 
In the model-based treatment scenario (Figure 3) information on the relationship between Cmin, baseline seizure 
rate and efficacy is used to determine the treatment plan for each individual. Depending on the baseline of 1-3, 3-
10, or >10 seizures per 3 months, patients’ target Cmins were set to 10, 12.5, or 15 mg/L respectively. Target 
doses (mg/dosing interval) were calculated that should result in Cmin levels at the target Cmin using equation 4. 
Patients were initiated with those doses for four weeks, after which a trough sample was taken regardless of the 
occurrence of seizures. If the trough concentration was above the threshold, treatment was maintained. If the 
trough concentration was below the threshold, the dose was increased using equation 5. After another 4 weeks, 
the patient was re-evaluated. If seizures had occurred, the treatment was deemed unsuccessful, if not, the 
treatment was deemed successful.  
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Figure 3. Representation of scenario 2 
 
ⱪⱶⱪݐⱪẘↄ	ẛⱷݏⱡ	ሺ௠௚ఛ ሻ ൌ
்௔௥௚௘௧	ᾣ௠௜௡
ቀ ҮభషӪషӄөᾯ
Ұ
భషӪషӆөି
ሺҮశҰሻ
భషӪషӶӢөቁ
        (4) 
ⱶⱡݓ	ẛⱷݏⱡ	 ቀ௠௚ௗ௔௬ቁ ൌ 	ⱷↄẛ	ẛⱷݏⱡ	 ቀ
௠௚
ௗ௔௬ቁ ∗ ሺ
்௔௥௚௘௧	ᾣ௠௜௡
ெ௘௔௦௨௥௘ௗ	ᾣ௠௜௡ሻ      (5) 
Where ߬ is the dosing interval. A, B, alpha (ߙ), beta (ߚ), and Ka are here the model-predicted values (not taking 
into account random variability). 
 
3. Results 
3.1.1. Exploratory pharmacokinetic simulations 
The individual pharmacokinetic profile of a single patient, with corresponding Cmin values is plotted in figure 4. 
From this graph we can see that daily fluctuations of TPM are fairly large, even when dosing bi-daily. As a 
consequence, attaining adequate Cmin levels while ensuring peak levels below toxic levels could be difficult. 
This is corroborated by figure 5, in which median and 95% prediction intervals of concentrations over time 
resulting from three dose levels (5, 10 and 15 mg/kg/day) are shown. Here we see that variability in the overall 
population is large, which points to the need for more individualised dosing. 
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Figure 4. Concentrations over time (blue line) and Cmin of each day (magenta line) for a typical patient after 
administration of 5 mg/kg twice daily (10 mg/kg/day) 
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Figure 5. Median and 95% prediction interval of exposures (Cmin) per dose level in the overall population 
 
3.1.2. Exploratory pharmacodynamic simulations 
Figures 6 and 7 show the median and 95% prediction interval of the seizure free percentage of the simulated 
population depending on Cmin or dose level respectively. It is clear from these graphs that either dose or Cmin 
levels have a profound impact on the percentage of the population having had at least one seizure, and thus on 
the probability of any such patient in the population having a seizure. It is also evident that the higher the 
baseline level of seizures, the higher dose or Cmin level is required to counteract it. Based on these graphs, we 
can surmise that target Cmin levels should be tailored to the individual patient’s baseline instead of treating all 
patients equally. 
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Figure 6. Median and 95% prediction interval of the seizure free percentage of the population over time, per 
Cmin level 
 
Figure 7. Median and 95% prediction interval of the seizure free percentage of the population over time, per dose 
level 
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3.2. Simulation scenarios 
3.2.1 Clinical scenario 1 
Concentrations over time resulting from scenario 1 are shown in figure 8 and give an idea of the change in 
exposure due to increases in dose for those patients with seizures. Given the relatively low (but clinically typical) 
starting dose, these patients do not achieve adequate exposure in the first weeks of treatment, and subsequently 
show that the percentage of the population not having had a seizure drops fairly rapidly (figure 9). The delay in 
adequate exposure by slow dosing increases results in many patients having to wait for adequate effect, but also 
may result in patients requesting to have a different drug, as the efficacy is perceived to be inadequate. 
 
Figure 8. Median and 95% prediction interval of exposures (Cmin) in scenario 1 
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Figure 9. Median and 95% prediction interval of the seizure free percentage of the population over time, for 
scenario 1 
 
3.2.2 Clinical scenario 2 
Figure 10 shows the median and 95% prediction interval of concentrations over time resulting from scenario 2. 
Although initially exposure may be a little more excessive than achieved at the end of scenario 1, the adjustment 
made after 28 days largely improves on this. Exposure at the end of the scenario is achieved at a higher median 
level, with a smaller fraction of patients having exposures above the therapeutic window. The higher median 
concentration levels also translate into efficacy, considering that the percentage of patients not having had a 
seizure is roughly 75%, while at this same point in time (56 days) this level is roughly 60% in scenario 1. 
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Figure 10. Median and 95% prediction interval of exposures (Cmin) in scenario 2 
 
Figure 11. Median and 95% prediction interval of the seizure free percentage of the population over time, for 
scenario 2 
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Discussion & conclusion 
In this brief exploratory simulation exercise we set out to understand how the implementation of a more rational, 
model-based dosing guidance would impact clinical practice both from a practical, and an efficacy point of view. 
These preliminary results show that, assuming all other things being equal, the model-based dosing rationale 
helps to i. better determine the required level of exposure, ii. achieve efficacious drug levels faster, and iii. take 
into account inter-individual variability to a significant degree by only requiring one TDM sample. Obviously 
the results shown here are only based on a simplified view of clinical practice, we dare not hope to simulate the 
immense variability that occurs in clinical practice to any decent degree in the nearby future. Instead, the current 
exercise is an example of how clinical practice could be made more rationale, using basic PKPD concepts and 
possibly PKPD model information. It is our view that such an application could improve response in this highly 
variable population, expressly because of its variability. 
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